Skip to Content
MilliporeSigma

1.16890

Fractogel® EMD SO3⁻ (S) Resin

strong cation exchanger, suspension in 20% ethanol and 150 mM NaCl (20-40 µm)

Synonym(s):

Fractogel® EMD SO3⁻ (S)

Slide 1 of 1
Sign In to View Organizational & Contract Pricing

Select a Size

10 ML

$77.50

100 ML

$605.00

500 ML

$2,120.00

5000 ML

Inquire

$77.50

Check Cart for Availability

About This Item

UNSPSC Code:
41115711

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

ligand

(Sulfoisobutyl)

Quality Level

100
400

assay

≥90% (HPLC)

form

resin

manufacturer/tradename

Calbiochem®

parameter

8 bar max. pressure
80 cm/hr flow rate

matrix active group

methacrylate

mean particle size

20-40 um μm

capacity

150 mg binding capacity (lysozyme/ml of resin)

transition temp

flash point 35 °C (Does not sustain combustion.)

density

1.43 g/cm3 at 20 °C

bulk density

1000 kg/m3

separation technique

strong cation exchange

shipped in

ambient

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
1.168821.168861.10317
Millipore

Millipore

1.16890

Fractogel® EMD SO3⁻ (S) Resin

Fractogel® EMD SO3 ⁻ (M) Resin strong cation exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)

Millipore

1.16882

Fractogel® EMD SO3 ⁻ (M) Resin

Fractogel® EMD COO- (M) weak cation exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)

Millipore

1.16886

Fractogel® EMD COO- (M)

Fractogel® EMD BioSEC (S) for size exclusion chromatography (SEC), suspension in 20% ethanol and 150 mM NaCl (20-40 µm)

Millipore

1.10317

Fractogel® EMD BioSEC (S)

ligand

(Sulfoisobutyl)

ligand

(Sulfoisobutyl)

ligand

carboxymethyl

ligand

(Modified pore structure)

form

resin

form

resin

form

resin

form

-

separation technique

strong cation exchange

separation technique

cation exchange, strong cation exchange

separation technique

cation exchange, weak cation exchange

separation technique

size exclusion (SEC)

sterility

sterile (Caustic Stable)

sterility

sterile (Caustic Stable)

sterility

sterile (Caustic Stable)

sterility

-

capacity

150 mg binding capacity (lysozyme/ml of resin)

capacity

130 mg binding capacity (lysozyme/ml of resin)

capacity

100 mg binding capacity (lysozyme/ml of resin)

capacity

-

matrix active group

methacrylate

matrix active group

methacrylate

matrix active group

methacrylate

matrix active group

Methacrylate

Packaging

  • 1.16882.0100: Fractogel® EMD SO3- (S) Resin 100ml
  • 1.16882.0010: Fractogel® EMD SO3- (S) Resin 10ml
  • 1.16882.0500: Fractogel® EMD SO3- (S) Resin 500ml
  • 1.16882.5000: Fractogel® EMD SO3- (S) Resin 5L

Analysis Note

Appearance: Milky turbid suspension, free from impurities (foreign particles)
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.05 %
Cerium: ≤ 10 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 5.0 bar
Particle size (d10): 20 - 28 µm
Particle size (d50): 24 - 34 µm
Particle size (d90): 28 - 38 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (lysozyme): 120 - 180 mg/ml
Functional test (c:d): ≤ 0.15
Functional test (b:a): ≤ 0.15
Functional test: Separation chymotrypsinogen A, cytochrom C and lysozyme

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

pictograms

Flame
GHS02

signalword

Warning

hcodes

H226

Hazard Classifications

Flam. Liq. 3

Storage Class

3 - Flammable liquids

wgk_germany

WGK 1

flash_point_f

95.0 °F

flash_point_c

35 °C

Stay compliant with GMP using the Emprove® Program

Accelerate qualification, maintain compliance, and save time with Emprove® Dossiers.

Download Dossiers

Note: you will be brought to EmproveSuite.com. Your username and password are separate from SigmaAldrich.com and may differ.

Register for free and access Emprove® Dossiers within minutes. Upgrade your subscription plan to unlock advanced and customized content in the Emprove® Suite

Not finding what you are looking for? Visit the Emprove® Program Help page.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E A Kowaluk et al.
The Journal of pharmacology and experimental therapeutics, 295(3), 1165-1174 (2000-11-18)
Adenosine kinase (AK; EC 2.7.1.20) is a key intracellular enzyme regulating intra-and extracellular concentrations of adenosine (ADO), an endogenous neuromodulator, antinociceptive, and anti-inflammatory autocoid. AK inhibition provides a means of potentiating local tissue concentrations of endogenous ADO, and AK inhibitors
D L Boyle et al.
The Journal of pharmacology and experimental therapeutics, 296(2), 495-500 (2001-02-13)
Adenosine (ADO) is a homeostatic inhibitory autocoid that is released at sites of inflammation and tissue injury, and exerts anti-inflammatory effects via multiple interactions at ADO receptor subtypes. Inhibition of ADO kinase (AK) increases extracellular ADO concentrations and AK inhibitors
R Suzuki et al.
British journal of pharmacology, 132(7), 1615-1623 (2001-03-27)
1. Adenosine (ADO) receptor activation modulates sensory transmission in the dorsal horn. Little is known about the circumstances underlying release of the purine. The present study was conducted to investigate the effect of a novel and potent non-nucleoside adenosine kinase
M F Jarvis et al.
The Journal of pharmacology and experimental therapeutics, 295(3), 1156-1164 (2000-11-18)
Adenosine (ADO) is an inhibitory neuromodulator that can increase nociceptive thresholds in response to noxious stimulation. Inhibition of the ADO-metabolizing enzyme adenosine kinase (AK) increases extracellular ADO concentrations at sites of tissue trauma and AK inhibitors may have therapeutic potential
Jean De Vry et al.
European journal of pharmacology, 491(2-3), 137-148 (2004-05-14)
The chronic constriction injury model is a rat model of neuropathic pain based on a unilateral loose ligation of the sciatic nerve. The aim of the present study was to test its sensitivity to various clinically validated and experimental drugs.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service